COVID-19: Responding to the business impacts of Rise in expanse of applications boosts Rheumatoid Arthritis Stem Cell Therapy market 2018 to 2028 3w…

Companies in the Rheumatoid Arthritis Stem Cell Therapy market are facing issues in keeping their production facilities fully functional due to shortage of staff and resources amidst the COVID-19 (Coronavirus) outbreak. Get a hands-on over key drivers and threats to the Rheumatoid Arthritis Stem Cell Therapy market to make your company future-ready post the pandemic. Avails out reports for exciting prices to learn new opportunities that companies can capitalize on during and after the Coronavirus crisis.

Latest Insights on the Global Rheumatoid Arthritis Stem Cell Therapy Market

According to the analysis of the research analysts at Fact.MR, the Rheumatoid Arthritis Stem Cell Therapy market is set to reach a market value of ~US$XX by the end of 20XX. Further, the study indicates that the Rheumatoid Arthritis Stem Cell Therapy market is expected to grow at a CAGR of ~XX% during the forecast period (20XX-20XX). The well-researched market report offers a thorough quantitative and qualitative assessment of the Rheumatoid Arthritis Stem Cell Therapy market along with easy to grasp tables, graphs, and figures.

The market study bifurcates the global Rheumatoid Arthritis Stem Cell Therapy market in different segments to enhance the reading experience of our clients.

Request Sample Report @ https://www.factmr.co/connectus/sample?flag=S&rep_id=1001

The various segments covered in the report are as follows.

Competitive outlook

The competitive outlook tracks the business proceeding of top-tier market players involved in the Rheumatoid Arthritis Stem Cell Therapy market. The company profile provides a clear understanding of the growth strategies adopted by various market players.

Competitive landscape

Request Methodology On This Report @ https://www.factmr.co/connectus/sample?flag=RM&rep_id=1001

Key takeaways from the presented market analysis:

The market analysis provides answers to some important questions related to the Rheumatoid Arthritis Stem Cell Therapy market:

Ask analyst about this report at https://www.factmr.co/connectus/sample?flag=AE&rep_id=1001

Reasons to Opt for Fact.MR

Excerpt from:
COVID-19: Responding to the business impacts of Rise in expanse of applications boosts Rheumatoid Arthritis Stem Cell Therapy market 2018 to 2028 3w...

Avrobio taps Magenta’s ADC in ongoing quest to improve gene therapy conditioning – FierceBiotech

Avrobio is working to make conditioning, a necessary step for some gene therapies, safer. But its not stopping at improving current approachesthe company is teaming up with Magenta Therapeutics to see whether an antibody-drug conjugate (ADC) can do the job.

Under the deal, the duo will test Magentas lead conditioning program, MGTA-117, alongside at least one of Avrobios gene therapies. Each company will hold onto the rights for their respective programs, but Avrobio will pick up the tab for clinical trials involving MGTA-117.

We believe targeted ADCs represent the next generation of medicines to prepare patients for gene therapy or transplant in a targeted, precise way This partnership will allow Magenta to validate our conditioning platform in lentiviral gene therapy applications, said Magenta CEO Jason Gardner, D.Phil., in a statement.

Avrobios lead program is a gene therapy for Fabry disease dubbed AVR-RD-01. It is based on CD34+ stem cells that have been modified using a lentiviral vector to carry and express the gene that codes for the enzyme that is missing in Fabry disease. It is also working on treatments for Gaucher disease, Cystinosis and Pompe disease.

RELATED: Avrobio posts encouraging update for Fabry gene therapy phase 1, 2 trials

Patients undergoing lentiviral gene therapies must first take the chemotherapy drug busulfan in a process called conditioning, which helps the gene-modified stem cells take root in their bone marrow. Avrobio uses therapeutic drug monitoring to tailor busulfan dosing to each patient, to improve the odds of success for its gene therapies while tamping down on side effects. Some patients may be more susceptible to infection and bleeding after conditioning, and they may suffer side effects like nausea, hair loss and mouth sores.

MGTA-117 is made up of an anti-CD117 antibody linked to amanitin, a cell-killing toxin. It is designed to target only hematopoietic, or blood-forming, stem cells and progenitor cells. Animal studies suggest it could clear space in bone marrow for gene-modified stem cells to take root, Magenta said in the statement. The company plans to wrap IND-enabling studies for the antibody-drug conjugate this year.

The deal comes on the heels of a busulfan-focused one for Avrobio. The company joined forces with Saladex Biomedical on Monday to develop a rapid blood test that monitors how quickly patients metabolize the drug. The hope is to get results in minutes, rather than the hours that current methods take, so dosing can be adjusted quickly.

Read the original here:
Avrobio taps Magenta's ADC in ongoing quest to improve gene therapy conditioning - FierceBiotech

Global Stem Cell Therapy Market 2020 With COVID-19 Update by Development factors analysis, Competitive Strategies and Forecast to 2025 – Bandera…

GlobalStem Cell TherapyMarket Report 2020, Forecast to 2025presents a historical overview of market size, revenue, share, forecast, and market drivers. The report features detailed insights and deep research on the globalStem Cell Therapymarket. The report studies various segments, as well as key opportunities in the market and influencing factors which will help businesses increase their footprints in the industry. A comprehensive analysis of the product scope and market risks has been given for the participants. The report shows the company profile of the major vendors along with their winning strategies to give business owners, stakeholders, and field marketing personal a competitive edge over others operating in the market.

Get Free Sample Report:https://www.magnifierresearch.com/report-detail/36202/request-sample

NOTE: Our analysts monitoring the situation across the globe explains that the market will generate remunerative prospects for producers post COVID-19 crisis. The report aims to provide an additional illustration of the latest scenario, economic slowdown, and COVID-19 impact on the overall industry.

The Market Report Addresses:

The report provides historical and forecasts market data including demand, application details, price trends, and company shares of the leading manufacturers by geography, and estimation of the globalStem Cell Therapymarket size by volume and value. The growth estimation of the market is offered on the basis of calculation by various segmentation and past and current data. This market has been divided into types, applications, and regions. The report also covers the growth aspects of the market along with the restraining factors which are expected to impact the overall growth of the market in the estimated forecast period from 2020 to 2025.

The top manufacturers/suppliers which are currently operating in the globalStem Cell Therapymarket industry includes:Mesoblast, Regeneus, U.S. Stem Cell

By the product type, the market is primarily split into:Monotherapy, Combination Therapy

By the end-users/application, this report covers the following segments:Osteoarthritis (unspecified), Knee Osteoarthritis, Shoulder Osteoarthritis, Hip Osteoarthritis

Market Regions and Countries Level Analysis:

Regional analysis is a highly comprehensive section of this report. This segmentation sheds light on the sales of theStem Cell Therapyon regional- and country-level. This data provides a detailed and accurate country-wise volume analysis and region-wise market size analysis of the global market. Market segmented by region/country:North America (United States, Canada and Mexico), Europe (Germany, France, UK, Russia and Italy), Asia-Pacific (China, Japan, Korea, India and Southeast Asia), South America (Brazil, Argentina, Colombia etc.), Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Access Full Report:https://www.magnifierresearch.com/report/global-stem-cell-therapy-market-report-2020-forecast-36202.html

Moreover, the report aims to deliver evaluation and essential information on the competitive landscape to meet the unique requirements of the companies and individuals operating in the market. The study recognizes the factors affecting the globalStem Cell Therapymarket growth such as drivers, restraints, opportunities, and trends. The report also recognizes emerging players with a potentially strong product portfolio and creates effective counter-strategies to gain competitive advantage. The report features reliable high-quality data and analysis which is suitable for supporting your internal and external presentations. The market research report will also help create regional and country strategies on the basis of local data and analysis.

Customization of the Report:This report can be customized to meet the clients requirements. Please connect with our sales team (sales@magnifierresearch.com), who will ensure that you get a report that suits your needs. You can also get in touch with our executives on +1-201-465-4211 to share your research requirements.

About Us

Magnifier Research is a leading market intelligence company that sells reports of top publishers in the technology industry. Our extensive research reports cover detailed market assessments that include major technological improvements in the industry. Magnifier Research also specializes in analyzing hi-tech systems and current processing systems in its expertise. We have a team of experts that compile precise research reports and actively advise top companies to improve their existing processes. Our experts have extensive experience in the topics that they cover. Magnifier Research provides you the full spectrum of services related to market research, and corroborate with the clients to increase the revenue stream, and address process gaps.

Contact UsMark StoneHead of Business DevelopmentPhone:+1-201-465-4211Email:sales@magnifierresearch.comWeb:www.magnifierresearch.com

Link:
Global Stem Cell Therapy Market 2020 With COVID-19 Update by Development factors analysis, Competitive Strategies and Forecast to 2025 - Bandera...

Cell Therapy Market 2020 by Various Types, End-Use Application, Major Players, Forecast 2025 – Cole of Duty

The Global Cell Therapy Market research report provides and in-depth analysis on industry- and economy-wide database for business management that could potentially offer development and profitability for players in this market. This is a latest report, covering the current COVID-19 impact on the market. The pandemic of Coronavirus (COVID-19) has affected every aspect of life globally.

Leading Companies Reviewed in the Report are:

JCR Pharmaceuticals Co., Ltd., Kolon TissueGene, Inc.; and Medipost and many more.

Get Sample Copy of this Report @ https://www.adroitmarketresearch.com/contacts/request-sample/611

This has brought along several changes in market conditions. The rapidly changing market scenario and initial and future assessment of the impact is covered in the report. Cell Therapy market Report offers critical information pertaining to the current and future growth of the market. It focuses on technologies, volume, and materials in, and in-depth analysis of the market. The study has a section dedicated for profiling key companies in the market along with the market shares they hold.

The research report on the global Cell Therapy market includes certain segments by type & application, region and major players. Each type offers data about the production during the slated period of 2015 to 2026. Whereas, the application segment also delivers consumption during the predicted timeframe of 2015-2026. Understanding the segments helps in recognizing the importance of distinct elements that aid the growth of the Cell Therapy market globally. Additionally, it provides in-depth analysis of growth rate and other factors of the global Cell Therapy market in pivotal regions.

Browse the complete report @ https://www.adroitmarketresearch.com/industry-reports/cell-therapy-market

Global Cell Therapy Market is segmented based by type, application and region.

Based on Type, the Market has been segmented into:

By Use & Type Outlook, (Clinical-use,By Cell Therapy Type,,Non-stem Cell Therapies,Stem Cell Therapies,BM, Blood, & Umbilical Cord-derived Stem Cells,Adipose derived cells,Others), By Therapeutic Area, (Malignancies,Muscoskeletal Disorders,Autoimmune Disorders,Dermatology,Others,Research-use), By Therapy Type, (Allogenic Therapies,Autologous Therapies)

The report provides a thorough assessment of the growth and other aspects of the Cell Therapy market in key regions, including the United States, Canada, Italy, Russia, China, Japan, Germany, and the United Kingdom United Kingdom, South Korea, France, Taiwan, Southeast Asia, Mexico, India and Brazil, etc. The main regions covered by the report are North America, Europe, the Asia-Pacific region and Latin America.

The research report on the world Cell Therapy market has been designed briefly by observing and examining various aspects that discover regional growth of the specific industry. Our analysts team has examined the production cost, revenue data, production, import/export details and key manufacturers of each region. It also evaluates region-wise volume and revenue for the forecast time period between 2020 to 2026. These investigations will help the reader to clearly understand the potential worth of expenditure in a specific region.

For Any Query on the Cell Therapy Market: https://www.adroitmarketresearch.com/contacts/enquiry-before-buying/611

About Us :

Adroit Market Research is an India-based business analytics and consulting company incorporated in 2018. Our target audience is a wide range of corporations, manufacturing companies, product/technology development institutions and industry associations that require understanding of a Markets size, key trends, participants and future outlook of an industry. We intend to become our clients knowledge partner and provide them with valuable Market insights to help create opportunities that increase their revenues. We follow a code- Explore, Learn and Transform. At our core, we are curious people who love to identify and understand industry patterns, create an insightful study around our findings and churn out money-making roadmaps.

Contact Us :

Ryan JohnsonAccount Manager Global3131 McKinney Ave Ste 600, Dallas,TX75204, U.S.A.Phone No.: USA: +1 972-362 -8199/ +91 9665341414

Go here to read the rest:
Cell Therapy Market 2020 by Various Types, End-Use Application, Major Players, Forecast 2025 - Cole of Duty

Stem Cell Treatment for COVID-19; Doctors Divided on Its Scope – The Quint

A team of doctors and researchers at the Abu Dhabi Stem Cell Center (ADSCC) administered the treatment in the UAE to 73 COVID-19 patients, who were all successfully treated and cured, without any immediate side effects, according to a statement by the United Arab Emirates (UAE) health ministry from 1 May.

The process involved a minimally invasive method where the patients stem cells are extracted, activated and turned into fine mist to be inhaled into the lungs. This was done in addition to the conventional treatment and is expected to work by supporting the established protocol of management of symptoms.

The ministry said in the statement, It is hypothesised to have its therapeutic effect by regenerating lung cells and modulating the immune response to keep it from overreacting to the COVID-19 infection and causing further damage to healthy cells.

The treatment has successfully undergone the initial phase of clinical trials, demonstrating its safety, and further trials for its efficiency are ongoing; expected to be completed in a couple of weeks.

Dr Fatima al-Kaabi, head of haematology and oncology at the Sheikh Khalifa Medical City in the UAE, told CNBC, Its very early to say at this stage. If all went well, this could reach the market in three months, she added.

Going further back, a pilot study in China on seven COVID-19 patients found that intravenous infusions of donor mesenchymal stem cells (MSC) - multipotent stem cells - improved patient outcomes and helped all of them recover. An Israeli pharmaceutical company, Pluristem Therapeutics, also tested stem cells in seven critical hospitalized patients and found positive results.

Additionally, the US Food and Drug Administration (FDA) approved MSC use in extremely sick COVID-19 patients under expanded access compassionate use on 5 April according to a report in The Scientist, even though the experts seemed divided on the logic on which the investigative treatment may have worked.

A hospital in New York tried the therapy as an experiment on 12 patients, 10 of whom were able to come off ventilators, reports CBS news. The Australian regenerative medicine company Mesoblast has also announced a 300-person trial for its stem cell therapy remestemcel-L (which was used in the New York trial) to determine whether it will work on patients suffering with severe lung inflammation.

Currently, there are over 20 active stem cell trials for COVID-19, most focusing on the use of MSCs.

View original post here:
Stem Cell Treatment for COVID-19; Doctors Divided on Its Scope - The Quint

Mike Tyson, 53, reveals he had stem cell research therapy and hadnt hit bags for 15 YEARS before returning t – The Sun

MIKE TYSON revealed how he has started training again having not thrown a punch for a staggering 15 years - and is being aided by stem-cell research therapy.

The Baddest Man on the Planet, who hung up his gloves in 2005 following defeat by Kevin McBride, wouldn't elaborate on why he was having the treatment but added that it was 'really wild what scientists can do'.

4

Tyson was having an Instagram chat with basketball legend Shaquille O'Neal when he revealed that he had been training for the previous three days after 15 years away - and his new health regime.

Iron Mike said: "You know what I had done? I had stem-cell research therapy.

"I feel like a different person but I can't comprehend why I feel this way. It's really wild what scientists can do."

Stem-cell therapy is the use of stem cells to treat or prevent a disease or condition that usually takes the form of a bone marrow transplantation.

He did not reveal what the exact condition was that was being treated.

Despite letting the gloves gather dust in the corner, it didn't take long for Iron Mike to show off that lethal punching power.

4

The 53-year-old delighted fans in lockdown by uploading a viral video of him laying into a punchbag with his trademark speed and power.

Tyson's weight ballooned after retiring following battles with drug addiction and depression.

But he has since partnered with a new trainer, MMA coach Rafael Cordeiro, to kick-start his training after sensationally revealing his 15-year break.

During their chat, basketball legend O'Neal revealed how he ached for three days after playing with his sons.

Tyson responded: "That's just because you haven't done it for a while.

WHAT IS STEM CELL TREATMENT USED FOR?

Stem cell transplants are carried out when bone marrow is damaged or isnt able to produce healthy blood cells.

It can also be used to replace damaged blood cells as the result of intensive cancer treatment.

Here are conditions that stem cell transplants can be used to treat:

"If you continue to do it consistently you'll be back to normal.

"It's just like me, I haven't boxed or hit the bag for 15 years - it has been three days so far and I feel incredible."

Tyson, who has a 50-6 record, is reportedly gearing up for a sensational return amid plans to compete in exhibition bouts for charity later this year.

He told rapper T.I. last month: "I've been hitting the mitts for the last week.

"That's been tough, my body is really jacked up and really sore from hitting the mitts.

MIKE DROPTyson shows off body transformation with 53-year-old preparing for boxing return

HOLY MOLYHolyfield hints at comeback aged 57 after Tyson announces plans to return to ring

NO GLOVE LOSTJoshua tells Froch to 'shut up, blud' as war of words continues

WHATSAPP-ENING?Joshua sent Froch four now-deleted messages after his P4P rant

IT WILL ALL END IN PIERSPiers Morgan and Eddie Hearn in Twitter spat over coronavirus

SHOWDOWNHall vs Bjornsson: How giants compare as Beast threatens deadlift record holder

NEED FOR SPEEDMike Tyson, 53, shows off speed as heavyweight legend gears up for return

HOME FIGHTERDubois enjoys lockdown sparring with siblings after buying family pad

DO OR TYMike Tyson's trainer 'saw life flash before his eyes' in scary training clip

"I've been working out, I've been trying to get in the ring, I think I'm going to box some exhibitions and get in shape.

"I want to go to the gym and get in shape to be able to box three or four-round exhibitions for some charities and stuff.

"Some charity exhibitions, make some money, help some homeless and drug-affected motherf****er like me."

4

4

Here is the original post:
Mike Tyson, 53, reveals he had stem cell research therapy and hadnt hit bags for 15 YEARS before returning t - The Sun

Century Therapeutics Announces Formation of Scientific Advisory Board – Business Wire

PHILADELPHIA--(BUSINESS WIRE)--Century Therapeutics, developer of induced pluripotent stem cell (iPSC)-derived allogeneic cell therapies for cancer, today announced the formation of its Scientific Advisory Board (SAB) to include several renowned experts in the fields of developmental and stem cell biology, genetics, and immuno-oncology. The SAB will work closely with Century as it develops off-the-shelf iPSC-derived adaptive and innate immune effector cell therapies to treat hematologic and solid malignancies.

We are privileged to welcome these distinguished scientists as inaugural members of our Scientific Advisory Board, said Lalo Flores, PhD, CEO at Century Therapeutics. Their expertise in disciplines central to the control of cellular differentiation and lymphocyte function as applied to the field of immuno-oncology will bring external scientific and clinical-translational perspectives to help guide Century in the development and expansion of our allogeneic cell therapy technology.

Centurys President of R&D, Hy Levitsky, M.D., said, Were looking forward to leveraging the deep scientific expertise and insights this elite group brings to bear on the design and development of both iPSC-derived CAR-NK and CAR-T cell products.

Centurys Scientific Advisory Board members are:

In addition to the creation of the science-focused SAB, Century will also convene a disease-focused clinical advisory board to be chaired by Dr. Marcela Maus who is a scientific co-founder of Century Therapeutics.

About Century Therapeutics

Century Therapeutics is harnessing the power of stem cells to develop curative cell therapy products for cancer that overcome the limitations of first-generation cell therapies. Our genetically engineered, universal iPSC-derived immune effector cell products (NK, T, DC and macrophage) are designed to specifically target hematologic and solid tumor cancers. Our commitment to developing off-the-shelf cell therapies will expand patient access and provides an unparalleled opportunity to advance the course of cancer care. Century was launched in 2019 by founding investor Versant Ventures in partnership with Fujifilm and Leaps by Bayer. For more information, please visit http://www.centurytx.com.

Visit link:
Century Therapeutics Announces Formation of Scientific Advisory Board - Business Wire

Liberal MP Jim Carr to receive stem-cell transplant to treat blood cancer – The Globe and Mail

Jim Carr speaks to the Calgary Chamber of Commerce, on Jan. 14, 2020.

Jeff McIntosh/The Canadian Press

Liberal MP and former cabinet minister Jim Carr is returning to hospital for a stem-cell transplant, a treatment that had been twice delayed due to the COVID-19 pandemic.

The Winnipeg MP shared the news on social media Tuesday morning, saying that he and his family remain grateful for all the support they have received since his cancer was discovered last fall.

He said he expects to be recovering in hospital for the next few weeks.

Story continues below advertisement

The past few months have been a challenging and unprecedented time for everyone but I know that we will get through this and emerge stronger than ever, he wrote in a message posted to Twitter.

Carr had been diagnosed with multiple myeloma after experiencing flu-like symptoms during the 2019 federal election campaign.

In his own social-media post Tuesday, Carrs son Ben said life has not been the same for the family since the diagnosis, but the fact his father had been campaigning with failing kidneys and cancer running through his blood spoke to his character.

Anyone who was with us during the campaign can tell you just how tough he is, he wrote.

Carr had headed into that campaign as the Liberals international trade diversification minister, and was one of only a handful of Liberals re-elected in the Prairie provinces in the October vote.

He stepped back from cabinet following his diagnosis to undergo treatment, though Prime Minister Justin Trudeau appointed him as a special representative for the region.

Less than a year ago he was Canadas trade minister, travelling around the world to make the country a better place, Ben Carr wrote.

Story continues below advertisement

Lately, hes been resigned to his living room. A pretty tough reality to confront, no question.

His son said the stem cell transplant had been cancelled twice because of COVID-19, and the pandemic is also forcing the family apart during an exceptionally difficult time.

For me personally, one of the worst parts of whats been happening is the loss of connection with my dad. Although we speak every day by video call, it isnt the same. No hugs, no shared meals, no sitting beside each other watching sports, he wrote.

He said normally hed go visit his father during his recovery, but this time wont be allowed in the hospital.

I love you, dad. See you on the other side.

Last fall, Carrs colleague Dominic Leblanc also underwent a stem-cell transplant, this one to treat non-Hodgkins lymphoma.

Story continues below advertisement

The New Brunswick MP had been diagnosed with that cancer in the spring of 2019.

Know what is happening in the halls of power with the days top political headlines and commentary as selected by Globe editors (subscribers only). Sign up today.

See the rest here:
Liberal MP Jim Carr to receive stem-cell transplant to treat blood cancer - The Globe and Mail

BioCardia Announces Positive Preclinical Results Supporting Investigational New Drug Application for Anti-Inflammatory Cell Therapy in Heart Failure -…

SAN CARLOS, Calif., May 05, 2020 (GLOBE NEWSWIRE) -- BioCardia, Inc.[Nasdaq: BCDA], a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today announced data from a recent animal study performed by the Company that demonstrate meaningful improvements in heart function for subjects treated with its allogenic (from another donor, or off the shelf) neurokinin 1 receptor positive mesenchymal stem cell (NK1R+ MSC) program for heart failure, known as CardiALLO. In addition, the Company is planning further exploration and discussion with the U.S. Food and Drug Administration (FDA) on the use of its allogenic cells for COVID-19 related Acute Respiratory Distress Syndrome (ARDS).

In the 26 animals treated with both low dose and high dose NK1R+ MSC, echocardiographic measures of cardiac ejection fraction, fractional shortening and cardiac outflow were meaningfully improved, with all three measures being statistically significant for both dosage levels over control animals.

The CardiALLO cell therapy is being developed initially to treat heart failure patients whose cells do not qualify for its lead autologous cell therapy, CardiAMP (BCDA-01).

BioCardia Chief Scientific Officer Ian McNiece, PhD, said, In light of these positive data on our allogenic NK1R+ MSC therapy, we expect to meet our internal timeline to complete our submission to the FDA for our first indication for CardiALLO, and potentially receive IND acceptance by the end of the second quarter. The MSCs that were studied are subtypes of MSC that we have delivered previously in our co-sponsored trials, which we believe have enhanced potency over MSC generated from unselected bone marrow cells. We look forward to seeing additional data from this animal study that are currently being analyzed, including histology and pathology of the heart and lungs.

COVID-19 Induced Acute Respiratory Distress Syndrome (ARDS) Exploration

The Company also intends to submit an IND for the use of its NK1R+ MSC delivered via intravenous (IV) infusion for Acute Respiratory Distress Syndrome (ARDS) caused by COVID-19.

Based on preliminary clinical reports on COVID-19, respiratory failure complicated by ARDs is the leading cause of death for COVID-19 patients.1 ARDS is a type of respiratory failure characterized by the rapid onset of widespread inflammation in the lungs.

The anti-inflammatory effects of MSC have been well-documented and MSC have been shown to reduce inflammation and injury in models of lung disease.2 The specific MSCs used in BioCardias allogenic cell therapy are expanded from cells selected for the presence of the NK1 receptor, which is known to bind to substance P, an important neuropeptide associated with inflammation throughout the body and a primary mediator of inflammation in the airways.3,4

Our NK1R+ allogenic MSC may have more potential than other MSC approaches being advanced today due to their interaction with Substance P, said BioCardia CEO Peter Altman, PhD. This COVID-19 related work will be the Companys first clinical investigation outside of the cardiac space and our first exploring therapy for the lung. A recent patent publication (US 2020/0101113 A1) shows that BioCardia has long intended for these remarkable reparative cells to be targeted for respiratory disorders, in addition to cardiovascular disease. Addressing inflammation in the lungs is an important contribution we may be able to make using our NK1R+ allogenic MSC therapy.

The Companys allogenic cells are expected to be manufactured at BioCardias clinical stage cell manufacturing facility in San Carlos, California.

About BioCardiaBioCardia, Inc., headquartered in San Carlos, California, is developing regenerative biologic therapies to treat cardiovascular disease. CardiAMP and CardiALLO cell therapies are the Companys biotherapeutic product candidates in clinical development. The Company's approved products include the Helix transendocardial delivery system and its steerable guide and sheath catheter portfolio. BioCardia also partners with other biotherapeutic companies to provide its Helix System and clinical support to their programs studying therapies for the treatment of heart failure, chronic myocardial ischemia and acute myocardial infarction.

Forward Looking Statements This press release contains forward-looking statements that are subject to many risks and uncertainties. Forward-looking statements include, among other things, references to the development of NK1R+ cells for the treatment of heart failure and ARDS secondary to COVID-19, potential FDA IND acceptances, and potential FDA filings, statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations. Such risks and uncertainties include, among others, the inherent uncertainties associated with developing new products or technologies. These forward-looking statements are made as of the date of this press release, and BioCardia assumes no obligation to update the forward-looking statements.

We may use terms such as believes, estimates, anticipates, expects, plans, intends, may, could, might, will, should, approximately or other words that convey the uncertainty of future events or outcomes to identify these forward-looking statements. Although we believe that we have a reasonable basis for each forward-looking statement contained herein, we caution you that forward-looking statements are not guarantees of future performance and that our actual results may differ materially from the forward-looking statements contained in this press release. As a result of these factors, we cannot assure you that the forward-looking statements in this press release will prove to be accurate. Additional factors that could materially affect actual results can be found in BioCardias Form 10-K filed with the Securities and Exchange Commission on April 9, 2020, under the caption titled Risk Factors. BioCardia expressly disclaims any intent or obligation to update these forward-looking statements, except as required by law.

Media Contact: Michelle McAdam, Chronic Communications, Inc.michelle@chronic-comm.com(310) 902-1274

Investor Contact: David McClung, Chief Financial Officerinvestors@BioCardia.com(650) 226-0120

See the original post here:
BioCardia Announces Positive Preclinical Results Supporting Investigational New Drug Application for Anti-Inflammatory Cell Therapy in Heart Failure -...

Canine Stem Cell Therapy Market To Extend An Assessed Value Of US$ 218.2 Mn By 2026 – Cole of Duty

Persistence Market Research (PMR) has published a new research report on canine stem cell therapy. The report has been titled, Canine Stem Cell Therapy Market: Global Industry Analysis 2016 and Forecast 20172026.Veterinary research has been used in regenerative and adult stem cell therapy andhas gained significant traction over the last decade.

Canine stem cell therapy products are identified to have gained prominence over the past five years, and according to the aforementioned research report, the market for canine stem cell therapy will expand at a moderate pace over the next few years.

Regions Covered In Report

Get Sample Copy of Report @ https://www.persistencemarketresearch.com/samples/15550

Company Profiles

Get To Know Methodology of Report @ https://www.persistencemarketresearch.com/methodology/15550

Though all animal stem cells are not approved by FDA, veterinary stem-cell manufacturers and university researchers have been adopting various strategies in order to meet regulatory approvals, and streamline and expedite the review-and-approval process. The vendors in the market are incessantly concentrating on research and development to come up with advanced therapy, in addition to acquiring patents.

In September 2017, VetStem Biopharma, Inc. received European patent granted to the University of Pittsburgh and VetStem received full license of the patent then. This patent will eventually provide the coverage for the ongoing commercial and product development programs of VetStem and might be also available for licensing to other companies who are rather interested in this field.

The other companies operating in the global market for canine stem cell therapy are VETherapy Corporation, Aratana Therapeutics, Inc., Regeneus Ltd, Magellan Stem Cells, Animal Cell Therapies, Inc., and Medrego, among others.

According to the Persistence Market Research report, the globalcanine stem cell therapy marketis expected to witness a CAGR of 4.2% during the forecast period 2017-2026. In 2017, the market was valued at US$ 151.4 Mn and is expected to rise to a valuation of US$ 218.2 Mn by the end of 2026.

Burgeoning Prevalence of Chronic Diseases in Dogs to Benefit Market

Adipose Stem Cells (ASCs) are the most prevalent and in-demand adult stem cells owing to their safety profile, ease of harvest, and use and the ability to distinguish into multiple cell lineages. Most early clinical research is focused on adipose stem cells to treat various chronic diseases such as arthritis, tendonitis, lameness, and atopic dermatitis in dogs.

A large area of focus in veterinary medicine is treatment of osteoarthritis in dogs, which becomes more prevalent with age. Globally, more than 20% dogs are suffering from arthritis, which is a common form of canine joint and musculoskeletal disease. Out of those 20%, merely 5% seem to receive the treatment.

However, elbow dysplasia in canine registered a prevalence rate of 64%, converting it into an alarming disease condition to be treated on priority. Thereby, with the growing chronic disorders in canine, the demand for stem cell therapy is increasing at a significant pace.

Access Full Report @ https://www.persistencemarketresearch.com/checkout/15550

Expensive Nature of Therapy to Obstruct Growth Trajectory

Expensive nature and limited access to canine stem cell therapy has demonstrated to be a chief hindrance forestalling its widespread adoption. The average tier II and tier III veterinary hospitals lack the facilities and expertise to perform stem cell procedures, which necessitates the referral to a specialty vet hospital with expertise veterinarians.

A trained veterinary physician charges high treatment cost associated with stem cell therapy for dogs. Generally, dog owners have pet insurance that typically covers maximum cost associated with steam cell therapy to treat the initial injury but for the succeeding measures in case of retreatment, the costs are not covered under the pet insurance. The stem cell therapy is thus cost-prohibitive for a large number of pet owners, which highlights a major restraint to the market growth. Stem cell therapy is still in its developmental stage and a positive growth outcome for the market cannot be confirmed yet.

Continued here:
Canine Stem Cell Therapy Market To Extend An Assessed Value Of US$ 218.2 Mn By 2026 - Cole of Duty